S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Accuray Stock Forecast, Price & News

-0.12 (-2.41%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
847,629 shs
Average Volume
1.38 million shs
Market Capitalization
$441.87 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

Accuray logo

About Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.


Earnings Estimates Rising for Accuray (ARAY): Will It Gain?
November 17, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$396.29 million
Cash Flow
$0.12 per share
Book Value
$0.50 per share


Net Income
$-6.31 million
Pretax Margin




Free Float
Market Cap
$441.87 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

1.92 out of 5 stars

Medical Sector

723rd out of 1,388 stocks

Surgical & Medical Instruments Industry

81st out of 126 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -

Accuray (NASDAQ:ARAY) Frequently Asked Questions

Is Accuray a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Accuray stock.
View analyst ratings for Accuray
or view top-rated stocks.

How has Accuray's stock price been impacted by Coronavirus (COVID-19)?

Accuray's stock was trading at $2.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARAY stock has increased by 114.1% and is now trading at $4.86.
View which stocks have been most impacted by COVID-19

When is Accuray's next earnings date?

Accuray is scheduled to release its next quarterly earnings announcement on Wednesday, January 26th 2022.
View our earnings forecast for Accuray

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.03. The medical equipment provider earned $107.44 million during the quarter. Accuray had a negative net margin of 1.85% and a positive trailing twelve-month return on equity of 3.19%.
View Accuray's earnings history

What guidance has Accuray issued on next quarter's earnings?

Accuray updated its FY 2022 earnings guidance on Thursday, November, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $420 million-$427 million, compared to the consensus revenue estimate of $415.82 million.

Who are Accuray's key executives?

Accuray's management team includes the following people:

What is Joshua Levine's approval rating as Accuray's CEO?

78 employees have rated Accuray CEO Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among Accuray's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.50%), Neuberger Berman Group LLC (5.49%), Renaissance Technologies LLC (4.33%), Heartland Advisors Inc. (3.74%), Dimensional Fund Advisors LP (2.43%) and Geode Capital Management LLC (2.07%). Company insiders that own Accuray stock include Brandon W Green, Byron C Scott, Jesse Chew, Joseph E Whitters, Joseph E Whitters, Joshua Levine, Patrick Spine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends for Accuray

Which institutional investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including HealthInvest Partners AB, Bank of New York Mellon Corp, Dimensional Fund Advisors LP, Russell Investments Group Ltd., Wellington Management Group LLP, BlackRock Inc., New York State Common Retirement Fund, and Deutsche Bank AG. Company insiders that have sold Accuray company stock in the last year include Brandon W Green, Jesse Chew, Joshua Levine, Patrick Spine, and Suzanne C Winter.
View insider buying and selling activity for Accuray
or view top insider-selling stocks.

Which institutional investors are buying Accuray stock?

ARAY stock was acquired by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Marshall Wace LLP, GSA Capital Partners LLP, Renaissance Technologies LLC, Harbert Fund Advisors Inc., Two Sigma Investments LP, Kovack Advisors Inc., and BNP Paribas Arbitrage SA. Company insiders that have bought Accuray stock in the last two years include Byron C Scott, Joseph E Whitters, and Joshua Levine.
View insider buying and selling activity for Accuray
or or view top insider-buying stocks.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $4.86.

How much money does Accuray make?

Accuray has a market capitalization of $441.87 million and generates $396.29 million in revenue each year. The medical equipment provider earns $-6.31 million in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does Accuray have?

Accuray employs 932 workers across the globe.

Does Accuray have any subsidiaries?

The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.

When was Accuray founded?

Accuray was founded in 1990.

What is Accuray's official website?

The official website for Accuray is www.accuray.com.

Where are Accuray's headquarters?

Accuray is headquartered at 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at (408) 716-4600, via email at [email protected], or via fax at 408-716-4601.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.